Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Differences in Legal Positioning of Package Inserts between Japan, US, Europe Highlighted
July 11, 2011
- Rivastigmine “Highly Effective”in Early Treatment of AD: Prof. Nakamura
July 11, 2011
- Pfizer Aims to Boost Sales of Long-listed Drugs by Adding Indications, Dosage Forms
July 11, 2011
- MAA Accepted by EMA for Perampanel: Eisai
July 11, 2011
- Rivastigmine Is Recommended for Mild AD: Dr Endo of NCGG
July 11, 2011
- Nippon Kayaku: Pharm Sales Up 1.3% to ¥50,339 Mil.
July 11, 2011
- Protect NHI Prices of Essential Drugs: Mr Matsumori of Pfizer Japan
July 11, 2011
- More Participation in Homecare Essential to Increase Demand for Pharmacists: Report
July 11, 2011
- Maruishi Expects Growth in Domestic Sales in FY2011
July 11, 2011
- Applications Based on Data from Public Domain Recommended for 8 Drugs
July 11, 2011
- NST Reduces Hospitalization Cost by ¥0.4 Mil per Patient: NCGM
July 11, 2011
- KHK Preparing for Expected Leap in Growth from 2014-2015: President Matsuda
July 11, 2011
- Korosho Abolishes Confirmation Application System for Regenerative Medicines
July 11, 2011
- MRs should Help Improve Quality of Healthcare as Medical Team Members: Prof. Muto
July 11, 2011
- Astellas Sells DPP-4 Inhibitor-related Patent Estate to Royalty Pharma for US$609 Mil.
July 11, 2011
- FDA Accepts Pfizer's Application for Axitinib for RCC
July 11, 2011
- Celecoxib Significantly Lowers Incidence of Ulcers vs Loxoprofen
July 11, 2011
- CMIC to Acquire Investigational Drug Manufacturing Facilities from Daiichi Sankyo
July 11, 2011
- Regenerative Medicine Industry Organization Kicks Off
July 11, 2011
- JES Calls for Approval of Monotherapy with Novel Antiepileptic Agents
July 11, 2011
ページ
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…